A former scientist at Google's DeepMind who co-developed the AlphaFold2 protein prediction platform, Dr Simon Kohl, has launched his own venture applying artificial intelligence to drug discovery.
Google parent Alphabet has drawn on its DeepMind artificial intelligence division to form a drug discovery unit that it calls Isomorphic Labs. The UK-registered company will be able to tap into ...
The New Normal Five years ago, COVID-19 was declared a global pandemic, marking the official onset of a healthcare crisis ...
Where is DeepMind’s AI protein design spinout ... In 2021, the company spun out Isomorphic Labs, an AI drug discovery company. But Isomorphic’s initial focus is on small-molecule drug ...
A new startup founded by a former Google DeepMind scientist is exiting stealth ... to “making biology programmable” — upending a drug-discovery process that currently relies on countless ...
Insilico Medicine, whose Hong Kong IPO application lapsed in 2024, is still considering going public in the city, said ...
DeepMind has also spun out its own drug discovery company, Isomorphic Labs. Kohl said Isomorphic was following the more common business model of partnering with pharma companies, and was taking a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback